CSI Market
Sign In | Register

Lexicon Pharmaceuticals Inc (LXRX) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access LXRX Annual Cash Flow →
Reviewing cash flow data across recent quarters allows users to assess how Lexicon Pharmaceuticals Inc adapts its cash strategy across cycles.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Jun 30 2026)
6 Months 		(Mar 31 2026) (Dec 31 2025) (Sep 30 2025) (Jun 30 2025)
Operating Activities
Income-32.82
Depreciation & amortization0.21
Amortization of Other Assets1.21
Increase (Decrease) in Deferred Revenue0.00
Business Exit Costs0.00
Provision For Loan Losses Expensed0.00
Increase (Decrease) in Inventories0.92
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property0.00
Share-based Compensation6.40
Income (Loss) from Equity Method Investments0.00
Gains (Losses) on Extinguishment of Debt-4.35
Amortization Of Symphony Icon Inc Purchase Option-
Stock Issued During Period Value Conversion Of Convertible Securities-
Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Liabilities-
Initial Recognition Of Right Of Use Asset-
Adjustments To Additional Paid In Capital Warrant Issued0.31
Gain On Sale Of Non Financial Assets-
Impairment Of Intangible Assets Excluding Goodwill-
Operating Lease Right Of Use Asset-
Treasury Stock Carrying Basis-
Stock Issued During Period Value Treasury Stock Reissued-
Income taxes0.00
Unrealized Gain (Loss) on Investments0.10
Increase (Decrease) in Accounts Receivable-0.74
Increase (Decrease) in Accounts Payable and Accrued Liabilities-2.00
Accrued Expense0.00
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets0.13
Other Working Capital-0.40
Other Noncash Income (Expense)0.10
Other net1.29
Payments for (Proceeds from) Other Operating Activities6.02
Discontinued operations0.00
Net Cash flow from Operating Activities-23.92
Investing Activities
Capital Expenditures0.00
Sale of Capital Items0.00
Short-term Investments Proceeds0.00
Short-term Investments Acq.0.00
Real Estate Investments0.00
Purchases Of Investments Held By Symphony Icon Inc-
Maturities Of Investments Held By Symphony Icon Inc-
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments-86.72
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-86.72
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings-4.26
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock71.07
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock26.55
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net-5.12
Other net0.00
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities88.24
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-23.92
Total Cash Flow-22.40
4 historic quarters locked

Sign in to unlock the full Lexicon Pharmaceuticals Inc cash flow history.

Sign In Create Free Account

About Lexicon Pharmaceuticals Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001062822-26-000117

Figures are derived from filed reports and may be restated. Historical data is subject to revision.